William Blair analyst Myles Minter has reiterated their bullish stance on NBIX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter has given his Buy rating due to a combination of factors that highlight Neurocrine’s strong performance and future growth potential. The company posted impressive third-quarter results, with Ingrezza surpassing both internal and consensus expectations, reaching all-time-high prescribing volumes. Despite a modest guidance for quarter-over-quarter growth, the company seems well-positioned to exceed these targets, especially considering the recent 10% growth reported.
Neurocrine’s strategic moves, such as expanding their salesforce and the anticipated CMS price negotiation for Austedo, are expected to bolster their market position. The launch of Crenessity in CAH has been notably successful, despite some volatility in new patient starts. Management remains optimistic about continued growth, supported by strong commercial execution and a promising pipeline of clinical catalysts. Overall, Neurocrine’s robust performance and strategic initiatives underpin Minter’s confidence in the company’s ability to achieve further top-line growth in the coming years.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $169.00 price target.